Danazol and Idiopathic Thrombocytopenic Purpura
letter
OA: closed
CC0
AI-generated summary
This letter questions whether observed improvements in platelet counts in patients with idiopathic thrombocytopenic purpura treated with danazol were solely due to the drug.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Letters and Corrections15 March 1990Danazol and Idiopathic Thrombocytopenic PurpuraMichael Phillips, MDMichael Phillips, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-3-112-6-474 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Does long-term treatment with danazol really benefit patients with autoimmune thrombocytopenia? Unfortunately, Dr. Ahn and colleagues (1) have not answered this question convincingly because their study did not incorporate controls who were not treated with danazol. The improved platelet counts observed in this uncontrolled "before and after" experiment could possibly have been due to factors other than danazol alone, for example, spontaneous improvement, placebo response, potentiation of the effects of glucocorticoids, or a combination of these effects.A study incorporating a placebo control group would answer these objections and would also be completely ethical because all subjects...References1. AhnRochaMylvaganamGarciaDuncanHarrington YRRRRW. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med. 1989;111:723-9. LinkGoogle Scholar2. McEvoy G Androgens. In: , ed. American Hospital Formulary Service Drug Information 89. Bethesda, Maryland: American Society of Hospital Pharmacists. 1989:1685-7. Google Scholar1. AhnMylvaganamRochaGarciaDuncanHarrington YRRRRW. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med. 1989;111:723-9. LinkGoogle Scholar2. RochaAhnMylvaganamHarrington RYRW. Danazol therapy for cyclic thrombocytopenia [Abstract]. Blood. 1988;72:1254a. Google Scholar3. HoseaSantaellaBrownBergerKatushaFrank SMEMKM. Long-term therapy of hereditary angioneurotic edema with danazol. Ann Intern Med. 1980;93:809-12. LinkGoogle Scholar4. MadanesFarber AM. Danazol. Ann Intern Med. 1982;96:625-30. LinkGoogle Scholar5. AhnRochaAntunezGarciaMylvaganamHarrington YRJRRW. Long term danazol therapy for idiopathic secondary autoimmune hemolytic anemias [Abstract 700]. Blood. 1989;74:187a. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Michael Phillips, MDAffiliations: St. Vincent's Medical Center of Richmond Staten Island, NY 10310-1699 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUpdate on diagnosis and treatment of immune thrombocytopeniaTargeted-immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia 15 March 1990Volume 112, Issue 6Page: 474-475KeywordsIdiopathic thrombocytopenic purpuraPlatelets ePublished: 1 December 2008 Issue Published: 15 March 1990 PDF downloadLoading ...
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
References (3)
- Danazol via openalex
- Long-Term Danazol Therapy in Autoimmune Thrombocytopenia: Unmaintained Remission and Age-Dependent Response in Women via openalex
- doi:10.7326/0003-4819-93-6-809 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T04:28:23.951474+00:00
License: CC0
· commercial use OK